Martin Prusinkiewicz, PhD

Postdoctoral Fellow, UBC

Menu

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273


Journal article


B. Grunau, Liam Golding, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, R. Armour, A. C. Márquez, A. Jassem, V. Barakauskas, S. O’Brien, S. Drews, Scott Haig, P. Lavoie, D. Goldfarb
Microbiology spectrum, 2022

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Grunau, B., Golding, L., Prusinkiewicz, M. A., Asamoah-Boaheng, M., Armour, R., Márquez, A. C., … Goldfarb, D. (2022). Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. Microbiology Spectrum.


Chicago/Turabian   Click to copy
Grunau, B., Liam Golding, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, R. Armour, A. C. Márquez, A. Jassem, et al. “Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus MRNA-1273.” Microbiology spectrum (2022).


MLA   Click to copy
Grunau, B., et al. “Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus MRNA-1273.” Microbiology Spectrum, 2022.


BibTeX   Click to copy

@article{b2022a,
  title = {Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273},
  year = {2022},
  journal = {Microbiology spectrum},
  author = {Grunau, B. and Golding, Liam and Prusinkiewicz, Martin A. and Asamoah-Boaheng, Michael and Armour, R. and Márquez, A. C. and Jassem, A. and Barakauskas, V. and O’Brien, S. and Drews, S. and Haig, Scott and Lavoie, P. and Goldfarb, D.}
}

Abstract

The BNT162b2 and mRNA-1273 mRNA SARS-CoV-2 vaccines have demonstrated high efficacy for preventing short-term COVID-19. However, comparative long-term effectiveness is unclear, especially pertaining to the Delta variant. ABSTRACT While mRNA vaccines are highly efficacious against short-term COVID-19, long-term immunogenicity is less clear. We compared humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months after the first vaccine dose, examining the wild-type strain and multiple Delta-variant lineages. Using samples from a prospective observational cohort study of adult paramedics, we included COVID-19-negative participants who received two BNT162b2 or mRNA-1273 vaccines, and provided a blood sample 170 to 190 days post first vaccine dose. We compared wild-type spike IgG concentrations using the Mann-Whitney U test. We also compared secondary outcomes of: receptor binding domain (RBD) wild-type antibody concentrations, and inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to spike proteins from the wild-type strain and five Delta-variant lineages. We included 571 adults: 475 BNT162b2 (83%) and 96 mRNA-1273 (17%) vaccinees, with a mean age of 39 (SD = 10) and 43 (SD = 10) years, respectively. Spike IgG antibody concentrations were significantly higher (P < 0.0001) for those who received mRNA-1273 (GM 601 BAU/mL [GSD 2.05]) versus BNT162b2 (GM 375 BAU/mL [GSD 2.33) vaccines. Results of RBD antibody comparisons (P < 0.0001), and inhibition of ACE-2 binding to the wild-type strain and all tested Delta lineages (all P < 0.0001), were consistent. Adults who received two doses of mRNA-1273 vaccines demonstrated improved wild-type and Delta variant-specific humoral immunity outcomes at 6 months compared with those who received two doses of the BNT162b2 vaccine. IMPORTANCE The BNT162b2 and mRNA-1273 mRNA SARS-CoV-2 vaccines have demonstrated high efficacy for preventing short-term COVID-19. However, comparative long-term effectiveness is unclear, especially pertaining to the Delta variant. We tested virus-specific antibody responses 6 months after the first vaccine dose and compared individuals who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. We found that individuals who received the mRNA-1273 vaccine demonstrated superior serological markers at 6 months in comparison with those who received the BNT162b2 vaccine.


Share



Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in